m6A modification: recent advances, anticancer targeted drug discovery and beyond

Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and aberrant m6A regulators have been identified as novel anticancer drug targets. Both traditional medicine-related approaches and modern drug discovery platfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Li-Juan, Deng, Wei-Qing, Fan, Shu-Ran, Chen, Min-Feng, Qi, Ming, Lyu, Wen-Yu, Qi, Qi, Tiwari, Amit K., Chen, Jia-Xu, Zhang, Dong-Mei, Chen, Zhe-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842557/
https://www.ncbi.nlm.nih.gov/pubmed/35164788
http://dx.doi.org/10.1186/s12943-022-01510-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842557/
https://www.ncbi.nlm.nih.gov/pubmed/35164788
http://dx.doi.org/10.1186/s12943-022-01510-2

Ejemplares similares